NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $11.71 +0.01 (+0.09 %) (As of 02/15/2019 04:00 PM ET)Previous Close$11.70Today's Range$11.58 - $11.9852-Week Range$6.22 - $25.29Volume662,013 shsAverage Volume1.17 million shsMarket Capitalization$1.25 billionP/E Ratio-10.94Dividend YieldN/ABeta2.68 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada. Receive SPPI News and Ratings via Email Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SPPI Previous Symbol CUSIP84763A10 Webwww.sppirx.com Phone702-835-6300Debt Debt-to-Equity RatioN/A Current Ratio2.65 Quick Ratio2.61Price-To-Earnings Trailing P/E Ratio-10.94 Forward P/E Ratio-13.16 P/E GrowthN/A Sales & Book Value Annual Sales$128.37 million Price / Sales9.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book3.36Profitability EPS (Most Recent Fiscal Year)($1.07) Net Income$-91,240,000.00 Net Margins-91.56% Return on Equity-27.72% Return on Assets-20.02%Miscellaneous Employees215 Outstanding Shares106,913,000Market Cap$1.25 billion OptionableOptionable Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions What is Spectrum Pharmaceuticals' stock symbol? Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI." How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.02. The biotechnology company had revenue of $24.17 million for the quarter, compared to analyst estimates of $27.58 million. Spectrum Pharmaceuticals had a negative return on equity of 27.72% and a negative net margin of 91.56%. The business's revenue for the quarter was down 29.5% on a year-over-year basis. During the same period last year, the firm posted ($0.11) earnings per share. View Spectrum Pharmaceuticals' Earnings History. When is Spectrum Pharmaceuticals' next earnings date? Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Spectrum Pharmaceuticals. What price target have analysts set for SPPI? 3 Wall Street analysts have issued 1-year target prices for Spectrum Pharmaceuticals' shares. Their predictions range from $19.00 to $40.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $26.6667 in the next twelve months. This suggests a possible upside of 127.7% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals. What is the consensus analysts' recommendation for Spectrum Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals. What are Wall Street analysts saying about Spectrum Pharmaceuticals stock? Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock: 1. HC Wainwright analysts commented, "Our $40 price target is derived from an NPV of Spectrum’s proprietary pipeline, a sum-of-the-parts analysis based on the P/E value of its current commercial business, plus cash. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 3x. We value the pipeline at $12.19 per share (x3= $36.57), the current commercial business at $1.48 per share and YE18 estimated fully diluted net cash at $1.49 per share." (1/10/2019) 2. According to Zacks Investment Research, "Spectrum Pharma is progressing well with its lead pipeline candidate, Rolontis, and a regulatory application is expected to be filed in 2018. A potential approval will boost the prospects of the company. However, Spectrum has faced regulatory setbacks in the past including rejection of regulatory application for Qapzola seeking approval for bladder cancer in the United States. Additional regulatory/development setbacks could affect the stock. However, out-licensing agreements for a number of products will allow Spectrum to focus on the development of its pipeline candidates. Spectrum’s shares have outperformed the industry so far this year. However, Spectrum's low product sales amid strong competition is a concern. Loss estimates have remained stable ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (11/16/2018) Has Spectrum Pharmaceuticals been receiving favorable news coverage? News articles about SPPI stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the next several days. Who are some of Spectrum Pharmaceuticals' key competitors? Some companies that are related to Spectrum Pharmaceuticals include FibroGen (FGEN), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO), Ascendis Pharma A/S (ASND) and Ultragenyx Pharmaceutical (RARE). Who are Spectrum Pharmaceuticals' key executives? Spectrum Pharmaceuticals' management team includes the folowing people: Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor RelationsMr. Keith M. McGahan J.D., L.L.M., Chief Legal Officer & Corp. Sec. Who are Spectrum Pharmaceuticals' major shareholders? Spectrum Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.47%), Macquarie Group Ltd. (2.22%), Northern Trust Corp (1.17%), Geode Capital Management LLC (1.08%), Bank of New York Mellon Corp (1.08%) and Dimensional Fund Advisors LP (0.94%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals. Which institutional investors are selling Spectrum Pharmaceuticals stock? SPPI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of Montreal Can, Ashford Capital Management Inc., Squarepoint Ops LLC, Northern Trust Corp, MetLife Investment Advisors LLC, California Public Employees Retirement System and Prudential Financial Inc.. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals. Which institutional investors are buying Spectrum Pharmaceuticals stock? SPPI stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Sargent Investment Group LLC, Millennium Management LLC, Oregon Public Employees Retirement Fund, Candriam Luxembourg S.C.A., Dimensional Fund Advisors LP, Geode Capital Management LLC and Fosun International Ltd. View Insider Buying and Selling for Spectrum Pharmaceuticals. How do I buy shares of Spectrum Pharmaceuticals? Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Spectrum Pharmaceuticals' stock price today? One share of SPPI stock can currently be purchased for approximately $11.71. How big of a company is Spectrum Pharmaceuticals? Spectrum Pharmaceuticals has a market capitalization of $1.25 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe. What is Spectrum Pharmaceuticals' official website? The official website for Spectrum Pharmaceuticals is http://www.sppirx.com. How can I contact Spectrum Pharmaceuticals? Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected] MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 358 (Vote Outperform)Underperform Votes: 253 (Vote Underperform)Total Votes: 611MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/15/2019 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?